GSK plc: Rebuilt Biopharma, Racing the Patent Cliff

From valuation, the stock is neither expensive nor plainly cheap. The London line closed at 1,983.5p on 2026-06-26, equal to roughly $52.35 per ADS at the same day’s FX rate, while the NYSE ADS closed at $52.50. On 2025 core EPS of 172.0p per ordinary share, the stock trades at roughly 11.6x trailing core earnings, with a trailing cash dividend yield a little above 3.3%. That is a discount to many high-quality large-cap pharma peers, but the discount is not irrational. The market is making investors pay only a moderate multiple because it wants proof that launches in oncology, respiratory and long-acting HIV can do more than cushion the cliff. At today’s price, the stock looks ownable for an existing holder and respectable for dividend-value investors, but it does not yet offer the sort of margin of safety that turns a good company into an easy buy.

2. Company vertical history

GSK’s origin story is not a startup story. It is a consolidation story. The current company traces back through Glaxo, Wellcome, SmithKline and Beecham, with the modern GSK created through the merger of Glaxo Wellcome and SmithKline Beecham in 2000. The old logic was scale: bigger science budget, broader global reach, more products, better negotiating power with health systems, and a portfolio diversified across prescription medicines, vaccines and consumer healthcare. That logic made sense in the era that produced the deal. What it did not guarantee was speed. Large pharmaceutical mergers often buy breadth at the cost of focus, and that trade-off shaped GSK for the next two decades.

There was no classic IPO to study because the company did not come to market as a newly funded venture. It emerged from the combination of two already listed pharmaceutical groups. The NYSE instrument is an ADR convenience for U.S. capital, not a separate operating listing. That matters because many U.S. screeners still treat the ADS as though it were an ordinary domestic share, which can distort market-cap presentations unless the two-share ADR ratio is handled correctly.

The first long stage was the conglomerate phase. GSK was large, global and profitable, but it looked more like a portfolio manager than a sharpened operator. The business mix included prescription medicines, vaccines and consumer brands; capital allocation often served portfolio balance as much as competitive intensity. For a time that was enough, but the industry changed faster than the group did. Patent cliffs got uglier, specialty medicines became more attractive than broad primary-care portfolios, and the market started to reward companies that were willing to look narrower but better. That change in investor preference did not create GSK’s problem by itself, but it made the problem impossible to hide. A company built for breadth was being judged on depth.

The second stage began under Emma Walmsley, who took over as CEO in 2017 after leading GSK’s consumer-health division. The appointment was controversial because critics wanted a scientist-operator. What Walmsley actually did was first organizational, then strategic. She pushed for simplification, raised the urgency around R&D productivity, and eventually separated the consumer-health business. That was the right move even if the market took a long time to reward it. In July 2022, the Haleon demerger completed, with GSK shareholders receiving one Haleon share for each GSK share held on the record date. This was the decisive break between “old GSK” and “new GSK.” From then on, the group had no excuse to hide pharma execution inside toothpaste and painkillers.

The third stage was the rebuild of credibility. A focused biopharma portfolio is useful only if the engines are genuinely strong. GSK had two. Shingrix turned out to be one of the most valuable vaccine franchises in large-cap pharma. ViiV, originally structured as a joint venture, became more attractive as the HIV market migrated toward two-drug oral regimens and then long-acting injectables. But credibility still lagged because the market had memories. GSK had previously exited oncology in a broad asset swap with Novartis, and investors wondered whether the company could really rebuild a cancer business after giving one up. It also carried Zantac litigation risk and the old complaint that pipeline promises arrived faster than proof. The market’s answer was to keep the multiple low until either legal overhang or pipeline execution changed that view.

The legal turn mattered more than it might appear from outside the sector. In late 2022, a U.S. federal judge dismissed thousands of Zantac cases, sharply reducing the market’s fear that GSK faced an open-ended legal liability. In 2024, after a Delaware court allowed a large state-court mass of cases to proceed, the shares fell sharply again. Then GSK settled roughly 80,000 U.S. state-court claims for up to $2.2bn in October 2024, resolving about 93% of the cases against it. The stock rose because the number was manageable and because fund managers finally had a cleaner range for downside liabilities. Litigation did not build the business. It did change the discount rate investors used to look at the business.

The fourth stage is the one investors are in now. Luke Miels became CEO on 2026-01-01 after serving as chief commercial officer since 2017. His appointment mattered because he was identified with the commercial build-out of specialty medicines and with a more aggressive, product-led pharmaceutical mindset. The change in leadership was not a repudiation of Walmsley’s strategy. It was the handoff from corporate surgery to commercial acceleration. The first months under Miels made that clear. GSK kept the >£40bn 2031 target, reiterated 2026 guidance, and moved harder on business development: RAPT Therapeutics for food allergy, 35Pharma for pulmonary hypertension, and then Nuvalent in a $10.6bn oncology deal aimed at building a lung-cancer platform. This is not the behavior of a management team merely defending a dividend stream. It is the behavior of a team trying to outrun a known patent problem before it arrives.

That is the central vertical conclusion. GSK has already proven it can shrink into a more coherent company. The question now is whether it can grow as one. The answer will depend less on whether management is willing to spend, and more on whether the spending turns into durable launches rather than expensive placeholders. The post-Haleon GSK story is no longer about cleaning up the front of the house. It is about whether the back room of science, manufacturing and commercial execution can carry the weight of the new narrative.

3. Financial vertical review

The long-run financial picture only becomes readable once the Haleon separation is treated as a genuine break in comparability. A ten-year spreadsheet exists, but the meaningful story is the last four or five years. Since the spin, GSK has become easier to read as a biopharma company because sales growth has tilted toward specialty medicines and away from the mature general-medicines base. In 2025, group turnover rose to £32.7bn, up 7% at constant exchange rates, driven mainly by specialty medicines, while vaccines were broadly stable and general medicines declined. That mix shift is the core financial fact of the company. Sales are not merely getting bigger. They are getting better.

Margin quality improved with that mix. In 2025, core cost of sales as a percentage of revenue fell because specialty medicines and regional mix contributed more, while operational efficiencies offset part of the pressure from Medicare Part D reform and pricing. Core operating profit rose to £9.8bn, up 11% at constant exchange rates. R&D still grew faster than sales, which is what management said it intended, but that is not automatically a problem here. GSK is in the stage where it has to invest ahead of the cliff. The right question is not whether R&D is high. The right question is whether the spend is buying commercially relevant programs quickly enough.

The cash picture is better than the old market stereotype suggested. In 2025, operating cash flow was £7.7bn and GSK’s own free-cash-flow reconciliation came to £4.0bn after capital expenditure, intangible investment, finance costs, joint-venture dividends and distributions to non-controlling interests. That free-cash-flow figure is the right place to pause because it shows both the strength and the complication of GSK’s economics. The business is a cash generator. But equity cash flow is not identical to operating profit because GSK has meaningful cash drains below the operating line, especially those tied to ViiV’s minority interests and Shionogi contingent payments. This is precisely why a headline core EPS multiple can overstate apparent cheapness.

There is also noise in total earnings quality. In 2025, total operating profit rose sharply to £7.9bn, but that number was helped by the absence of the prior year’s large Zantac charge and by settlement income, including CureVac-related mRNA patent settlements booked in other items. Total results are real IFRS results and cannot be ignored. But they are a poor guide to recurring earning power because they move around with litigation, contingent-consideration remeasurements, and fair-value changes. GSK itself tells investors to rely more on core results for guidance because total results cannot be forecast reliably when contingent liabilities and put-option valuations are moving around with FX and sales assumptions. That is reasonable as far as it goes; it also means investors should always reconcile back to cash.

The balance sheet is healthier than the share-price history might suggest. Net debt ended 2025 at £14.5bn, against core EBITDA of £11.3bn, for a net-debt-to-core-EBITDA ratio of 1.3x. That is modest for a large-cap pharma company and gives management room to fund deals like RAPT, 35Pharma and Nuvalent without taking the business into obvious financial danger. The stranger liabilities sit elsewhere: the ViiV put option, acquisition-related contingent consideration, and the large Shionogi-related contingent obligation that still stood at £5.4bn at year-end 2025. Investors who look only at conventional leverage are missing part of the picture. GSK is not overlevered in the classic sense. It is contractually encumbered in ways that make cash attribution more complex than the debt ratio suggests.

Returns on capital have improved economically, but they are not cleanly visible in the reported series because restructuring, legal charges, business-scope change and buybacks all muddy the accounting. The more useful operational read is this: as revenue has migrated toward Shingrix, HIV, oncology and respiratory biologics, the business has needed less faith in legacy primary-care scale and has earned more from differentiated, harder-to-copy assets. That is the kind of mix shift that usually supports higher ROIC over time. Whether the improvement persists will depend on what happens after dolutegravir, not on what happened before Haleon.

4. Price and valuation history

Over the past decade, GSK’s share-price history has been a story of changing labels. For a long stretch, the market treated the company as a mature cash generator with limited growth and too much organizational baggage. The stock was not loved for quality the way AstraZeneca was, and it was not loved for yield the way deeply out-of-favor big pharma sometimes is. It sat in the middle: useful, but not exciting.

The first major shift came with the idea of separation. Elliott’s 2021 intervention pushed governance and strategic options to the front, while the Haleon demerger reframed the equity as a focused biopharma name. That should have triggered a cleaner rerating, but the process was interrupted by two things: the Zantac cloud and concern that the streamlined company might still lack enough pipeline punch. So the stock did not move in a single revaluation. It lurched between strategic hope and legal fear.

The second major shift came when legal fear started to ease. The December 2022 federal-court dismissal of many Zantac claims lifted both GSK and Sanofi. The June 2024 Delaware setback reversed part of that relief and knocked nearly £7bn off GSK’s value in one day. The October 2024 settlement then reset expectations again, and the February 2026 full-year results pushed the shares to a multi-decade high as investors responded to the £2bn buyback, stronger specialty-medicines growth and the upgraded 2031 ambition. In short, the rerating was not driven by rates or macro liquidity alone. It was driven by a narrowing of legal downside and a growing willingness to believe the focused-biopharma version of GSK could grow faster than the old conglomerate.

Today’s valuation sits in an unusual spot. On the London line, the trailing P/E shown by retail market data is about 11.5x, and that lines up closely with 2025 core EPS of 172.0p. That multiple is low beside many large-cap pharma names and far below high-growth peers such as AstraZeneca. Yet it is not distressed value. It is a market saying the business is good, the cash flows are real, the dividend is credible, but the durability of the next decade still needs proof. That is why GSK can look inexpensive in a screen and merely fair in a full report.

5. Business model and moat

GSK makes money from three distinct engines, and the ranking matters. Specialty medicines are the growth engine. Vaccines are the franchise engine. General medicines are the cash-harvest engine. In 2025 the split was £13.5bn, £9.2bn and £10.0bn respectively, but that simple segmentation understates where the value sits. General medicines still matter, particularly Trelegy and older established brands, yet the center of gravity has moved decisively toward specialty assets and vaccines, where pricing, differentiation and duration are stronger.

The real machine is built around a few product clusters. In vaccines, Shingrix is the flagship, and it is more than a good product. It is a product that changed the category. CDC guidance recommends Shingrix for adults 50 and older and for certain immunocompromised adults, while Zostavax is no longer available in the United States. That means GSK is not fighting a superior rival in shingles. It is fighting under-vaccination, reimbursement boundaries and the normal friction of adult vaccination. In HIV, the ViiV portfolio is being remixed away from older dolutegravir combinations like Triumeq and toward Dovato, Cabenuva and Apretude. In respiratory and immunology, Nucala and Benlysta anchor a business that benefits from harder-to-replicate biologics rather than commodity-style primary care. In oncology, the story is no longer just Zejula. It is Blenrep’s re-entry, Jemperli’s label expansion, Ojjaara’s uptake, and the conscious attempt to build a larger platform through targeted M&A.

The cost structure reflects that mix. Gross margins and operating margins benefit when specialty medicines and vaccines grow faster than general medicines. The expensive line is R&D, and in a company like GSK that is not optional. This is not a business that can protect its moat by underinvesting. In fact, underinvestment is the most direct way to destroy value because the moat here is legal, scientific and manufacturing-based, not retail-based. GSK’s own reporting makes clear that R&D is intended to grow ahead of sales, while SG&A is supposed to become more selective as product focus narrows and productivity programs continue. That is the right shape of spending for this stage of the company.

The moat is real in four places.

First, vaccines. Vaccine franchises are not built overnight because the barrier is not only patents. It is also adjuvant know-how, global manufacturing validation, lot consistency, cold-chain reliability, procurement relationships and long regulatory memory. Shingrix is the best example. Once a vaccine becomes the preferred product and competitors disappear or lag, the moat rests partly in science and partly in systems. That is a better moat than one based only on branding.

Second, HIV formulation and long-acting execution. GSK and Gilead dominate U.S. HIV, but they do so with different strengths. Gilead owns the high-adherence oral standard with Biktarvy. GSK owns the strongest long-acting injectable treatment position with Cabenuva and the first long-acting injectable prevention option with Apretude. The moat here comes from formulation, clinical data, provider workflow, patient switching dynamics and a commercial organization that has learned how to move patients from oral regimens to injectables. GSK says 79% of Cabenuva switches in the U.S. came from competitors and that over one-third of total U.S. HIV sales now come from long-acting injectables. That is not a simple patent moat. It is a channel-and-practice moat built on product form.

Third, manufacturing scale where it matters. Biopharma scale is not generic scale. It matters only when it lowers risk, not when it merely adds volume. In GSK’s case, the scale advantage shows up in vaccines manufacturing, complex biologics and the ability to support global launches across the U.S., Europe and Japan. The post-2025 business-development push also assumes this advantage: buying clinical assets is only valuable if you can move them through global development, launch and supply at pace.

Fourth, commercial stickiness in specialty medicine. HIV, severe asthma, lupus and hematology are not markets won by advertising. They are won by evidence, protocol integration, specialist trust and reimbursement follow-through. That does not make GSK invulnerable, but it makes displacement slower and more expensive than in primary care.

The weaker moats are the ones investors sometimes overstate. GSK does not have a platform moat in the way a digital network has one. It does not have unmatched oncology scale. And its broad “big pharma” identity is not itself a moat. The true defenses are narrower than the company’s old brand image. That is one reason the post-Haleon restructuring helped. It forced investors to look at the sources of protection that actually exist.

On management and governance, the company now looks more credible than it did at the start of Walmsley’s tenure, though not beyond challenge. Luke Miels brings commercial biopharma depth from GSK, AstraZeneca, Roche and Sanofi, while CFO Julie Brown brought stronger financial discipline after arriving in 2023. Chair Jonathan Symonds adds governance and life-sciences experience. The structure is straightforward for a UK plc: no dual-class share system, a conventional board, and a buyback-plus-dividend capital-return framework. The credibility test is not governance design. It is whether management can keep capital allocation disciplined while using M&A to patch real future revenue holes. The last six months show willingness to spend. The next three years will show whether they were paying for bridges or merely buying time.

6. Industry and cycle

GSK sits inside several industries at once, and each has a different profit pool. Vaccines are a scale-and-trust business. HIV is a long-duration specialty market where adherence, resistance management and patient support shape economics. Respiratory biologics are a specialist-prescriber market increasingly defined by head-to-head efficacy, dosing convenience and payer economics. Oncology is the most competitive of the four, with the largest upside and the weakest legacy position for GSK.

This is not a classic macro cycle stock. Drug demand is largely defensive. The relevant cycles are regulatory, patent, scientific and payer-driven. A pharma company can have healthy volume and still lose half its value if a cornerstone product loses exclusivity before the replacement wave arrives. That is GSK’s true cycle. It is moving through a portfolio cycle, not a demand cycle. The variables that matter most are launch quality, exclusivity duration, advisory-committee recommendations, reimbursement, and the timing of label expansions.

The vaccine business shows how regulation can alter the growth curve without changing the franchise. RSV was the clearest example. CDC guidance now recommends an RSV vaccine for all adults 75 and older and for adults 50–74 at increased risk, and emphasizes that it is currently a single-dose vaccine rather than an annual shot. That narrowed and reshaped near-term expectations for Arexvy, helping explain why the vaccine business has looked less exciting than the Shingrix franchise. This was not a scientific collapse. It was a recommendation-driven resizing of the market.

Policy also cuts through HIV economics. Medicare redesign, pricing pressure outside the U.S., and future patent cliffs all matter more than GDP growth. Meanwhile, the global HIV need remains large. UNAIDS estimated roughly 40.8 million people were living with HIV in 2024, with 1.3 million new infections during the year and 31.6 million on therapy. That is a durable public-health demand base. It does not mean every product wins. It means the market remains large enough that regimen innovation and adherence benefits carry real economic value.

Geopolitics has become a live issue for large pharma again, but not in the old export-control sense. For GSK, the current version is supply chain and tariff policy. GSK said in 2025 it was positioned to mitigate potential U.S. tariff effects through supply-chain and productivity actions, and the U.K.-U.S. pharmaceutical arrangement finalized in 2026 provided at least temporary tariff protection for qualifying British medicines. That lowers one near-term risk, but it does not eliminate policy exposure. U.S. pricing policy and reimbursement remain larger structural issues than tariffs.

7. Horizontal competitor analysis

GSK does not have one perfect comparable company, so the right horizontal method is to compare franchise by franchise and then ask how the capital market prices the bundle. Four peers matter most for that exercise: AstraZeneca, Merck, Gilead and Pfizer. Sanofi also matters in immunology and vaccines, but the first four are the clearest listed references for the portfolio investors actually trade against GSK.

AstraZeneca became the company GSK was once expected to be and never quite was: a globally scaled, innovation-first large-cap pharma group that built real leadership in oncology and respiratory and earned a premium multiple for it. In 2025 AstraZeneca generated $58.7bn of revenue with double-digit core EPS and a much thicker oncology engine than GSK. Customers choose AstraZeneca because it offers depth across many tumor types and because its respiratory business has its own durable specialist franchise. The market pays a premium because AstraZeneca has already crossed the “can the pipeline replace the cliff?” bridge several times. GSK still has to prove it in this cycle.

Merck is the opposite comparison: concentrated excellence with a looming cliff bigger than GSK’s. In 2025 Merck produced $65.0bn in sales, with Keytruda alone at $31.7bn, or 49% of total sales. Merck’s oncology scale is far ahead of GSK’s, and its vaccine franchise remains powerful even with the China-related Gardasil setback. Customers choose Merck’s oncology portfolio because Keytruda became the standard backbone across multiple settings. Investors compare GSK with Merck not because the product maps are identical, but because both are living through the same capital-markets problem: the need to show that tomorrow’s growth drivers are big enough before today’s anchor franchise matures. Merck’s cliff is larger in absolute dollars, but its oncology starting point is vastly stronger. GSK’s relative challenge is different: build enough new growth from a smaller current cancer base.

Gilead is the most direct peer where it hurts. In HIV, Gilead remains the oral-regimen powerhouse. In 2025 its HIV product sales were $20.8bn, with Biktarvy alone at $14.3bn. Gilead’s recent approval of twice-yearly lenacapavir for prevention adds a serious new challenge to the prevention side of the market. Customers choose Gilead for oral simplicity and deep treatment familiarity; they choose GSK when long-acting injectables solve adherence, preference or workflow problems better. This is why the HIV contest is not winner-take-all. It is also why GSK’s moat is narrower than investors sometimes imply. In treatment, Cabenuva is differentiated. In prevention, Apretude now faces a prevention product with a longer dosing interval.

Pfizer is less similar scientifically but useful as a markets comparison. It is a large-cap pharma dividend asset with vaccines exposure, a major patent-replacement burden, and a post-COVID need to convince investors that business development can replace fading legacy revenues. Customers choose Pfizer less for category leadership in GSK’s core areas and more for breadth. Investors use it as a reminder that a low multiple in big pharma is not automatically cheap; sometimes it simply means the market doubts the replacement cycle. GSK is in better shape than Pfizer on portfolio coherence, but Pfizer’s experience after the COVID windfall is a useful warning about how fast confidence can evaporate if growth becomes acquisition-dependent rather than launch-dependent.

The niche GSK occupies is clear. It is a high-quality challenger in global biopharma: leader in shingles vaccines, co-leader in HIV with a distinct long-acting position, credible in respiratory and immunology, and rebuilding in oncology rather than leading it. That mix is unusual. It means no single peer captures the whole company, but it also means the market can mark the stock down whenever one pillar appears vulnerable because there is no overwhelmingly dominant platform business to carry the whole valuation. AstraZeneca has oncology depth. Gilead has HIV depth. Merck has oncology scale and vaccine heft. GSK has a more balanced set of good businesses without one business large enough to silence future-cliff anxiety on its own.

8. Current fundamentals and bull/bear divergence

The last four reported quarters show a business that is still moving in the right direction, but with enough noise to keep debate alive. Quarterly core sales moved from £7.5bn in Q1 2025 to £8.0bn in Q2, £8.5bn in Q3, £8.6bn in Q4, and £7.6bn in Q1 2026. Core EPS moved from 44.9p to 46.5p to 55.0p to 25.5p in the seasonally weaker Q4 and back to 46.5p in Q1 2026. Across that run, specialty medicines were the reliable driver. Vaccines were mixed, with Shingrix growing while Arexvy weakened. General medicines continued to decline. The trend is exactly what management wants: the good businesses are carrying the company faster than the old ones are shrinking.

Q1 2026 was the clearest current read. Sales were £7.6bn, up 5% at CER. Specialty medicines rose to £3.2bn, up 14%, with RII up 16%, oncology up 28% and HIV up 10%. Vaccines rose 4% to £2.1bn, with Shingrix at £1.026bn, up 20%, while Arexvy fell 18% to roughly £0.1bn. General medicines fell 6% to £2.3bn, with Trelegy flat. Core operating profit rose 10% and core EPS rose 9%. That is the operating picture in one sentence: GSK is growing because specialty and Shingrix are strong enough to offset the drag elsewhere.

What is the market trading right now? Two things. The first is the 2031 ambition and whether the bridge is believable. Reuters reported that analysts were still modeling only about £35bn of 2031 sales when GSK reiterated the >£40bn target in April 2026. The second is management activism under Luke Miels. The market read the February 2026 results and the June 2026 Nuvalent acquisition as a sign that Miels intends to move faster than his predecessor on asset acquisition and pipeline acceleration. That narrative has partly positive and partly negative consequences. Positive, because investors wanted urgency. Negative, because urgency in pharma usually means writing checks before the data are complete.

The bull case rests on specific evidence. Shingrix remains a rare adult-vaccine asset with category leadership and room for penetration growth across multiple geographies. ViiV’s HIV portfolio is being remixed toward products that still have runway, with Dovato, Cabenuva and Apretude more than offsetting Triumeq’s decline in 2025. Q1 2026 showed that long-acting HIV continued to gain weight, with more than 70% of HIV growth coming from the LAI portfolio and more than one-third of total U.S. HIV sales now from LAIs. Oncology is also no longer just a restructuring story: Jemperli, Ojjaara and Blenrep are showing real commercial traction, while Nuvalent adds a more serious lung-cancer platform than GSK previously had. Put together, that makes the 2031 bridge difficult but not fanciful.

The bear case also rests on specific evidence. First, HIV is still the company’s most important future problem. Management’s own 2031 assumptions explicitly extend only through dolutegravir loss of exclusivity and assume no premature loss of exclusivity on key products. That wording is revealing because it tells you exactly where the bridge becomes fragile. Second, vaccines are less uniformly powerful than the Shingrix narrative suggests. Arexvy’s slowdown shows how quickly recommendation changes can shrink a launch that once looked enormous. Third, business development has accelerated sharply in 2026. That may be necessary, but it also raises the chance that GSK pays up for pipeline before the underlying science is mature enough to deserve the price. Finally, Q1 2026’s market reaction showed that investors remain suspicious of one-off boosts and headline beats when the long-term replacement argument is still unsettled.

9. Valuation analysis

9.1 Historical valuation

On trailing 2025 core EPS, GSK trades at about 11.6x, and the trailing dividend yield on the London line is a little above 3.3%. That places the stock below many innovation-led big-pharma peers but above the valuation one would normally assign to a structurally broken or balance-sheet-stressed company. The market is not pricing GSK for failure. It is pricing it as a respectable but not yet fully trusted compounder.

Historically, the center of valuation has shifted because the business changed. Conglomerate GSK deserved a lower multiple than focused GSK. But focused GSK still gets a lower multiple than AstraZeneca because the market has seen AstraZeneca already convert science into scale. What changed at GSK was the direction of travel, not yet the level of proof.

9.2 Peer valuation

Relative to peers, GSK screens cheap on trailing earnings. Merck trades around 36.2x trailing EPS on the finance feed, Gilead around 17.4x, and Pfizer around 18.5x; AstraZeneca’s current U.S. price against 2025 core EPS implies roughly 20.6x. GSK’s own trailing multiple sits near 11.6x on 2025 core EPS. Some of this gap is justified. AstraZeneca and Merck own larger, better-proven oncology engines. Gilead owns a larger HIV base. Pfizer is less directly comparable, but its multiple shows investors will still pay more than GSK’s multiple for a company they believe can stabilize its decline. GSK’s discount is therefore partly a skepticism discount and partly a duration discount.

9.3 Absolute valuation

9.3.0 Cash-flow passthrough

The cleanest starting point is cash. In 2025, GSK generated £7.741bn of cash from operating activities and £4.029bn of free cash flow on its own reconciliation after capital expenditure, intangible investment, finance costs, joint-venture dividends and minority distributions. On roughly 2.0bn ADS-equivalent shares, that is about $2.65 of free cash flow per ADS. At $52.50, the stock trades on roughly a 5.0% trailing free-cash-flow yield, or just under 20x FCF.

GSK does not disclose a maintenance-versus-growth capex split, so any owner-earnings calculation is approximate. A conservative working assumption is to treat most net PPE spend as maintenance and a minority of purchased intangibles as maintenance, given that much true pipeline R&D is already expensed. On that basis, owner earnings for equity holders are closer to the mid-$3 range per ADS than to the $2.65 reported free-cash-flow figure. That leaves GSK trading around the mid-teens on owner earnings rather than the low-teens on core EPS. The stock still looks reasonable, but less obviously cheap than the headline core P/E suggests. The right conclusion is that GSK is a cash-generative equity with acceptable valuation, not a clear bargain.

This is valuation-scenario analysis within a research framework, not investment advice.

Using the scenario set above, I place conservative fair value around $47, base fair value around $53–58, and optimistic fair value around $60–66 per ADS. That does not produce a “broken stock” cheapness signal. It produces a “quality business, ordinary entry point” signal.

9.4 Expectation-gap analysis

The market is currently pricing two expectations that can still move. The first is that GSK can keep pushing specialty growth fast enough that the HIV cliff arrives into a stronger, broader earnings base. The second is that Luke Miels will use external business development as a supplement rather than as life support. The expectation gap lives in the middle. If current launches scale faster than consensus expects, the stock can rerate without heroic pipeline wins. If they merely behave decently while the company keeps buying pipeline, investors may conclude that the 2031 target is mathematically possible but economically expensive.

At the next major result, the market is likely to focus on four data points: Shingrix growth outside the U.S.; the pace of Cabenuva and Apretude expansion relative to new prevention competition; the quality of Blenrep and Jemperli launch metrics; and any clues on whether post-Nuvalent capital allocation remains disciplined. Those are the metrics that can still force a gap between what the market thinks it is buying and what it is actually getting.

9.5 Margin-of-safety recheck

Against the conservative scenario, the current price offers little margin of safety. On my framework, conservative fair value is around $47. At $52.50, the stock trades above that level.

The most fragile assumption in the base case is not Shingrix. It is the speed with which HIV replacement and oncology scaling narrow the hole left by eventual dolutegravir erosion. If I haircut the base scenario’s replacement assumptions to 70% of plan, the implied value collapses back toward roughly $46–49, which is very close to the conservative case.

If earnings are flat for the next three years and the share price also stays flat, the return is mostly the dividend. On the current implied dividend, that is roughly mid-3% annualized, below the 4.4% area on the U.S. 10-year Treasury around the report date. There is no margin of safety at this buy price.

This is a good-company-but-not-a-great-price case. For a holder, that is acceptable. For a new buyer, patience is defensible.

Margin-of-safety sufficiency verdict: not obvious.

10. Risk analysis

The biggest business risk is a replacement shortfall in HIV. Probability: medium. Impact: high. Observable indicators: slowing Dovato/Cabenuva/Apretude growth, weaker switch metrics, or evidence that prevention share is moving faster toward longer-interval alternatives. Transmission path: HIV is a large profit contributor, so weaker replacement growth would hit revenue durability, drag group mix, and make the 2031 bridge look less credible, which would almost certainly compress the multiple as well as earnings.

The next risk is pipeline and business-development execution. Probability: medium. Impact: high. Observable indicators: delayed pivotal readouts, tepid launch curves for Blenrep and Jemperli, or acquisitions that add spend without improving the slope of post-2028 revenue. Transmission path: if management has to keep paying for pipeline because internal and acquired launches do not scale, free cash flow gets squeezed, the dividend competes harder with R&D and M&A, and the market begins to price GSK more like a serial replenisher than a durable innovator. The rapid 2026 acquisition cadence is why this risk now matters more than it did a year ago.

A third risk sits in vaccines, specifically recommendation risk. Probability: medium. Impact: medium. Observable indicators: changes in CDC or other national guidance, weak initial uptake seasons, or evidence that the adult-RSV category remains smaller than originally modeled. Transmission path: vaccines have high economic value because they can scale globally, but their near-term revenue ramps are unusually sensitive to policy wording. Arexvy already showed how a recommendation change can recut the addressable market and shrink what investors thought was a blockbuster launch. Shingrix is more resilient, but no adult-vaccine asset is completely insulated from policy.

The fourth risk is accounting and cash-attribution complexity around ViiV. Probability: medium. Impact: medium to high. Observable indicators: higher contingent-consideration remeasurements, larger Shionogi cash payments, or disclosure that the post-Pfizer structure leaves less of ViiV’s economic upside flowing to GSK ordinary shareholders than investors assume. Transmission path: this does not usually hurt reported sales, because ViiV is consolidated. It hurts the quality of those sales from the perspective of GSK equity valuation because a growing portion of that cash may be spoken for through minority interests and contingent obligations.

The fifth risk is legal and policy tail risk. Probability: low to medium. Impact: high if it materializes. Observable indicators: renewed adverse court decisions on residual Zantac matters, aggressive U.S. pricing policy changes, or broader tariff and reimbursement disruptions. Transmission path: legal and policy shocks do not need to be large enough to wreck the income statement to damage the share-price narrative. GSK’s own history proves that. When investors fear the unknown size of a liability or policy change, they lower the valuation multiple first and ask accounting questions later.

11. Catalysts and tracking indicators

The positive catalysts are straightforward. Stronger-than-expected Shingrix demand in Europe, Japan and China would reinforce the idea that the vaccine still has a long penetration runway. Continued long-acting HIV growth, especially if Cabenuva keeps winning competitor switches, would make the HIV replacement story easier to believe. Early commercial evidence from Blenrep and Jemperli that confirms durable uptake would help investors view oncology as a real contributor rather than a perpetual option. A disciplined closing and integration path for Nuvalent could also matter because it would tell the market that Miels’ faster pace does not mean looser standards.

The negative catalysts are just as clear. A soft vaccine season outside Shingrix, disappointing long-acting HIV growth versus expectations, weaker oncology launch metrics, or readouts that push late-stage assets to the right would all damage the 2031 bridge. Because the market is already trading the bridge, not just the next quarter, guidance can remain intact and the stock can still struggle if the intermediate data start to look thinner.

These indicators matter for different reasons. Shingrix and HIV are the proof points that the current cash engine is intact. Oncology growth is the proof point that replacement is becoming real. Net debt and free cash flow tell you whether the company is financing ambition from operations or from future promises. The consensus gap on 2031 sales is especially useful because it shows whether the market is warming to management’s bridge or refusing to believe it. The Treasury yield is the outside variable: if a defensive big-pharma name offers a thin earnings yield premium to government bonds, the stock needs growth proof, not just stability, to rerate.

12. Cross-synthesis summary

GSK’s full journey shows one proven capability more clearly than any other: the company can build valuable franchises in complex, regulated categories where trust, manufacturing and specialist commercial execution matter. That is what Shingrix proves. It is what ViiV proves in a different way. The company’s long period of underwhelming market returns does not erase those capabilities; it shows that possessing them is not the same as arranging them into an equity story that compounds smoothly. For years, GSK had real assets inside an awkward structure. The Haleon demerger fixed the structure. The market is now testing whether the remaining assets can carry the stock without the old conglomerate ballast.

The source of past success was mixed. Some of it was era tailwind, especially the older broad-pharma scale logic that dominated when the modern company was formed. Some of it was management willingness to prune the portfolio and accept short-term pain to make the remaining company more coherent. Some of it was plain scientific and commercial strength in narrow areas, especially vaccines and HIV. The reason investors still hesitate is that those success factors are uneven in their durability. The organizational simplification happened already. It cannot be harvested twice. Shingrix still looks robust. HIV still looks valuable. But the future depends less on having a good old portfolio and more on the company’s ability to turn launches and acquisitions into a good new one.

Horizontally, GSK’s real advantage versus competitors is not that it beats all of them in one field. It does not. AstraZeneca has the stronger oncology machine. Gilead has the dominant daily oral HIV franchise. Merck has far greater oncology mass. What GSK has is a rarer combination: a genuinely elite vaccine asset in Shingrix, a distinctive long-acting HIV position, a credible respiratory and immunology business, and an oncology platform that is finally large enough to matter. That combination gives it more resilience than a single-franchise company, but less obvious dominance than a leader like AstraZeneca in its chosen core markets. GSK’s weakness is partly temporary and partly structural. The temporary part is oncology scale, which can still be built. The structural part is that its best businesses are not all synchronized in duration. One pillar is mature, one is mid-transition, and one is being assembled.

That is why the current valuation matters so much. The market is no longer rewarding past weakness. It is partly pre-spending future success. Not to an extreme degree; nothing about 11.6x core EPS and a 3.3%-plus dividend yield looks euphoric. But the rerating since the Zantac cleanup and the 2031 upgrade means investors are now being asked to own a plan, not just a cash stream. The plan says Shingrix stays strong, long-acting HIV keeps gaining weight, oncology launches accumulate, and selected acquisitions fill the remaining gap. The risk is not that this is impossible. The risk is that it proves slower, narrower or more expensive than the current narrative assumes.

The market’s likely misjudgment today is subtle. Many investors still discuss GSK as though it were simply a plodding large-cap dividend pharma, and that is too harsh. The evidence from 2025 and Q1 2026 says the business mix is improving, oncology is becoming commercially visible, and the HIV franchise is shifting toward products with ongoing growth. At the same time, some newer bulls are talking as though the proof burden has already been discharged. It has not. The market is right to ask how much replacement depends on internal science and how much depends on writing larger external checks. The truth sits between the two camps: GSK is better than its old discount, but not yet as durable as its best peers.

For the next year, the most critical variable is not total sales growth. It is quality of growth. Investors need to see that Shingrix, HIV LAIs and oncology are carrying enough of the increase to make the declining base progressively less important. For the next three years, the key variable is the post-dolutegravir bridge: whether current launches and acquired oncology assets are large enough, soon enough, to offset the early edge of the HIV cliff. For the next five years, the question becomes even more demanding: whether GSK can become a company whose valuation is driven by confidence in repeatable pipeline delivery rather than by the current cash harvested from already-proven products.

The stock would become a better investment under two conditions. One is price: a retreat into the high $30s to mid-$40s would create the margin of safety that is currently missing. The other is proof: if long-acting HIV, Blenrep, Jemperli and the newer respiratory and oncology programs show enough commercial pull that the 2031 bridge narrows from possibility to probability, GSK would deserve a higher multiple even without a cheaper entry point. That is why waiting is defensible but not costless. The opportunity cost is giving up a dividend stream above 3% and the possibility that management’s current acceleration works faster than skeptics expect.

12.1 Bull and bear reasons

Bull reasons:

• Shingrix remains the preferred shingles vaccine in the U.S. and the category leader in a market where the main competitor has exited, giving GSK a durable vaccine profit pool.
• ViiV’s HIV mix is improving, with Dovato, Cabenuva and Apretude offsetting Triumeq decline and long-acting products driving most HIV growth.
• The balance sheet is strong enough to fund pipeline investment and targeted M&A without obvious leverage stress, with 2025 net debt at only 1.3x core EBITDA.
• Oncology is no longer just a rebuild story; Jemperli, Blenrep, Ojjaara and the Nuvalent deal give GSK a more credible second growth curve.
• The stock still trades on a lower multiple than many peers, which leaves room for rerating if the post-2028 bridge becomes more believable.

Bear reasons:

• Management’s own 2031 assumptions explicitly run through dolutegravir loss of exclusivity, which tells investors the cliff is real and central, not hypothetical.
• Arexvy showed that adult-vaccine economics can change quickly when ACIP or CDC recommendation language changes, reducing confidence in non-Shingrix vaccine growth.
• ViiV cash flows are partly encumbered by non-controlling interests, contingent payments to Shionogi and historically complex preferential-dividend mechanics.
• The 2026 business-development pace increases execution risk and raises the chance that GSK overpays for assets to defend the 2031 target.
• At the current price, the dividend-driven return on a flat-earnings case does not beat the U.S. 10-year Treasury yield, so the stock lacks a clear margin of safety.

12.2 Pre-mortem: where might I be wrong

A plausible 50% down script over three years would start in HIV. Gilead’s prevention franchise scales faster than expected with longer-interval products, Cabenuva and Apretude growth slows materially, and investors stop believing that GSK can replace dolutegravir-family earnings organically. At the same time, the oncology rebuild underdelivers: Blenrep’s relaunch is merely adequate, Jemperli’s label expansion is slower than hoped, and Nuvalent’s assets launch later or smaller than expected. Group earnings stagnate, the market decides the 2031 target was too ambitious, and the multiple compresses from the current low-teens on core earnings toward high-single-digits on owner earnings. A fall of that size would not require financial distress. It would require a broken replacement story.

A second script would start with capital allocation rather than products. Management continues to buy pipeline at premium prices in 2026–2028, but clinical readouts disappoint or commercial launches fail to accelerate. R&D plus acquisition spend absorbs cash that investors expected would support both the dividend and growth, free cash flow weakens, and the market begins to see GSK as a company buying uncertain assets to patch a known cliff. In that version, the stock could halve even if Shingrix stays healthy, because one strong franchise is not enough to protect the multiple when the market stops trusting the bridge.

12.3 Final research conclusion

GSK today is a much better business than the share-market caricature that followed it for most of the last decade. The company has already done the structural work that needed to be done: the consumer-health split is behind it, the legal overhang is narrower than it was, the cash engines in Shingrix and ViiV are plainly visible, and the balance sheet can support both the dividend and selective business development. Those are not small achievements. They are the reason the stock no longer deserves to trade like a muddled conglomerate.

The harder question is whether that improvement is enough at the current price. I do not think the answer is an unqualified yes. What matters now is not whether GSK owns good assets. It does. What matters is whether the company can turn a good set of current franchises into a durable post-2028 earnings base without leaning too heavily on expensive acquisitions or on pipeline hopes that are still one or two steps from proof. The valuation is respectable, not stretched, but neither does it offer the margin of safety that would compensate a new buyer for that uncertainty. My judgment is that GSK is a credible long-term holding for investors who already own it, especially those who care about dividend income and large-cap defensive exposure, but it is a stock to buy more aggressively only at a better price or after more evidence that the replacement bridge is working.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: strong
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: dividend / value

【Investment rating】

• Rating: Hold
• One-line thesis: Focused biopharma GSK is stronger than its old reputation, but the current price already assumes much of the Shingrix-ViiV bridge before the HIV cliff is fully replaced.
• Three price signals:
  • Ideal buy price: 【Ideal Buy Price】38–45 USD Basis: at least a 20% margin of safety below my conservative value of roughly $47 per ADS.
  • Acceptable hold price: 46–60 USD
  • Clearly overvalued price: 66 USD and above
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A price in the low-to-mid $40s, or a materially stronger body of evidence on oncology and long-acting HIV replacement, would improve the risk-reward. The opportunity cost of waiting is mainly the 3%-plus dividend and the possibility of a rerating if the 2031 bridge gains credibility quickly.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative 0%–3%; base 6%–9%; optimistic 11%–13%
• Max-loss risk: roughly 45%–55% in a severe bear case, triggered by a combination of HIV replacement shortfall, weaker launch execution in oncology, and multiple compression toward high-single-digit owner-earnings multiples
• Reassessment-trigger signals:
  • if Shingrix posts two consecutive quarters of flat or negative CER growth without a clear inventory explanation
  • if long-acting HIV ceases to provide the majority of ViiV growth for two consecutive quarters
  • if oncology growth drops to low-single-digits before Nuvalent contributes
  • if net debt rises above 2x core EBITDA without clear acquired earnings support
  • if management materially weakens the link between free cash flow and dividend cover

【Valuation Range】

• current: 52.50 (close as of 2026-06-26)
• bear (conservative · ideal buy zone): [38, 45]
• base (fair · acceptable hold zone): [46, 60]
• bull (optimistic · above the clearly-overvalued line): [66, 74]

13. Key data tables

The numbers show a company whose quality is rising because the revenue mix is changing, not because it is slashing its way to a temporary margin lift. Free cash flow also improved sharply in 2025, but the balance sheet remains more complicated than the leverage ratio alone implies because ViiV-related obligations and acquisition contingent payments sit underneath the simpler debt story.

This table makes the current business mix tangible. The most important thing to notice is not any single number. It is the direction of the migration: older HIV products fading, long-acting and newer specialty medicines gaining weight, and oncology finally becoming large enough to matter to the quarterly growth bridge.

The reason GSK sits below AstraZeneca and below most large-cap peers is not simple neglect. It is that the market still prices AstraZeneca as a proven innovation compounder, while GSK is priced as a company with real franchise quality but with a cliff-and-replacement debate still unresolved. That discount can narrow, but it has to be earned.

14. Research uncertainties

The first blind spot is post-transaction ViiV economics. Public disclosures clearly show the ownership change from Pfizer to Shionogi and the accounting treatment of the Pfizer put option, but they do not yet provide a fully clean, recurring post-close earnings-allocation template that would let investors map future attributable cash flows with precision.

The second is the maintenance-versus-growth capex split. GSK does not disclose it, so any owner-earnings framework requires judgment. I have used a conservative approximation, but a different assumption would change the implied owner-earnings valuation.

The third is the exact shape of the post-dolutegravir cliff. Management discloses assumptions through the loss-of-exclusivity period, but outside investors still have limited precision on the timing and depth of erosion by product and region.

The fourth is the ultimate value of 2026 business development. Nuvalent, RAPT and 35Pharma materially improve the optionality of the pipeline, but the revenue and margin contribution of those deals remains partly speculative at this stage.

The fifth is market-data quality on the ADS line. Some data vendors appear to mis-handle the ADR ratio when presenting market cap. This report uses the London ordinary-share capitalization translated into dollars to avoid that distortion.

15. Sources

• GSK Annual Report 2025 / Form 20-F, quarterly results, ADR programme, investor materials, and press releases on ViiV, RAPT, 35Pharma and Nuvalent.
• GSK history, Haleon demerger materials, and leadership pages.
• CDC shingles and RSV guidance.
• UNAIDS global statistics and HIV update materials.
• Peer company primary disclosures: AstraZeneca, Merck, Gilead and Pfizer.
• Market data and macro references: web finance feeds, Hargreaves Lansdown, Nasdaq ADR page, FX history, and Federal Reserve H.15.
• Reuters reporting on Elliott, Haleon, Zantac, quarterly reactions, tariff and policy issues, and the Nuvalent acquisition.

Other tickers mentioned

• AZN.US: closest large-cap UK peer in oncology and respiratory, and the premium-valuation reference
• MRK.US: oncology and vaccines benchmark, and a useful patent-cliff comparison
• GILD.US: the key HIV peer, especially in daily oral regimens and long-acting prevention
• PFE.US: large-cap dividend and vaccines peer, and the former ViiV minority owner
• SNY.US: immunology and vaccines comparison, especially around adult vaccines and launch discipline
• REGN.US: co-economic owner of Dupixent, the leading respiratory and immunology biologic comparator
• HLN.LSE: 2022 demerger context for the consumer-health separation
• NUVL.US: acquired oncology platform central to GSK’s 2026 strategy shift
• RAPT.US: 2026 food-allergy acquisition supporting the RII pipeline This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.